Successful Treatment of Childhood Nail Lichen Planus with Ruxolitinib Cream: A Case Report.

IF 2.2 4区医学 Q3 DERMATOLOGY

Clinical, Cosmetic and Investigational Dermatology Pub Date : 2025-09-14 eCollection Date: 2025-01-01 DOI:10.2147/CCID.S542446

Anqi Sheng, Wenting Hu, Ai'e Xu

引用次数: 0

Abstract

The role of oral JAK inhibitors in the treatment of nail lichen planus (NLP) has recently been reported, but there have been no literature reports on the treatment of NLP with topical Janus kinase (JAK) inhibitor. We present, for the first time, a preliminary clinical experience with topical ruxolitinib cream, a JAK inhibitor, in a child with NLP. The remarkable results suggest topical ruxolitinib cream may be a potential treatment option for NLP.

Abstract Image

查看原文本刊更多论文

鲁索利替尼乳膏治疗小儿甲扁平苔藓1例。

口服JAK抑制剂在治疗扁平指甲苔藓（NLP）中的作用最近有报道，但没有关于局部Janus激酶（JAK）抑制剂治疗扁平指甲苔藓（NLP）的文献报道。我们首次提出了局部ruxolitinib乳霜（一种JAK抑制剂）治疗NLP患儿的初步临床经验。这些显著的结果表明，局部鲁索利替尼乳膏可能是NLP的潜在治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical, Cosmetic and Investigational Dermatology Medicine-Dermatology

CiteScore

2.80

自引率

4.30%

发文量

353

审稿时长

16 weeks

期刊介绍： Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Normal and pathological processes in skin development and aging, their modification and treatment, as well as basic research into histology of dermal and dermal structures that provide clinical insights and potential treatment options are key topics for the journal. Patient satisfaction, preference, quality of life, compliance, persistence and their role in developing new management options to optimize outcomes for target conditions constitute major areas of interest. The journal is characterized by the rapid reporting of clinical studies, reviews and original research in skin research and skin care. All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally.